Notably, anti-CD49d antibody in combination with iNKT cell transfer plus αGC injection significantly enhanced anti-tumor efficacy of iNKT cells, as indicated by reduced MC38 tumor growth (Fig. 8f–h), increased tumor infiltration of iNKT cells, and enhanced IFN-γ production in intratumoral iNKT cells (Fig. 8i–j), in comparison with iNKT cell transfer plus αGC injection alone. The gene discussed is ITGA4; the disease is neoplasm.